-

Chemspeed and SciY Announce Self‑Driving Laboratory Platform Integrating Automation, Analytics and AI Orchestration

BOSTON--(BUSINESS WIRE)--At SLAS2026, Chemspeed Technologies, a leader in the automation and digitalization of R&D and QC laboratories, and SciY, a leader in scientific and laboratory management software focused on lab standardization and AI-readiness, today introduce their open Self‑Driving Lab (SDL) platform. Their Self-Driving Lab platform is designed to accelerate research and development (R&D), quality control (QC) and chemical and biomolecular manufacturing workflows. The SDL enables lab managers to operationalize autonomous, AI‑orchestrated experimentation through vendor‑agnostic integration that unites modular precision automation, scientific analysis and lab management software, complete lab digitization and an AI‑ready open data backbone.

Today, many labs face significant challenges from siloed tools and integration gaps in heterogeneous lab environments that limit efficiency and scalability. The diversity of hardware and software systems often results in incomplete connectivity, incompatible data formats, and fragmented workflows. These constraints slow discovery, development and manufacturing QC processes, and hinder the transition towards autonomous AI‑enabled operations.

The Chemspeed/SciY open SDL platform provides this digital lab foundation and integrates the laboratory environment. Outstanding analytics, for NMR, IR/Raman, MS and X‑ray, ensures the traceable, quantitative data required in critical decisions. Chemspeed’s precision automation delivers modular, vendor‑agnostic control over complex laboratory workflows with deterministic, reproducible execution. SciY’s AI‑ready open data backbone unifies instruments and robotics data, workflow automation and orchestration with vendor‑agnostic FAIR (Findable, Accessible, Interoperable, Reusable) data capture, curation, governance and ontology‑driven semantics.

“Vendor‑agnostic orchestration is key. With our open SDL, we enable decision‑making in closed‑loop design–make–test–analyze (DMTA) workflows towards continuous 24/7 operations,” said Bernd Gleixner, the President of Chemspeed. “We are delivering not only a platform, but a service engine that accelerates discovery, supports compliant scale‑up and increases throughput across customers’ value chains.”

“We are seeing strong market interest by leading pharmaceutical partners,” said Santi Dominguez, the President of SciY. “This confirms that customers are looking for open, readily deployable full stack SDLs, and we are partnering with them to scale autonomous operations across sites and use cases.”

Chemspeed and SciY are vendor-agnostics divisions of Bruker Corporation (Nasdaq: BRKR).

About Chemspeed

Chemspeed Technologies, a Bruker division, empowers scientists and engineers to accelerate discovery, development, and QC (including regulated markets) with modular robotics, automation platforms and standardized systems across the laboratory workflow. From single function benchtop systems to integrated, vendor agnostic self-driving labs, Chemspeed solutions address complex tasks in synthesis, compound management, sample preparation, formulation, and testing, and are designed for closed loop, AI-ready operations that improve data quality and productivity. For over 25 years, Chemspeed has served R&D and QC organizations in pharma & biotech, materials science, energy/battery, and consumer goods, and is headquartered in Switzerland. For more information, please visit: www.chemspeed.com

About SciY

SciY, a Bruker division, provides vendor‑agnostic digitalization and orchestration solutions that connect scientific instrumentation, automation hardware, and information systems across research, development, and GMP manufacturing. Our platform connects these systems and their data into a unified digital environment where information is ingested, standardized, re‑used and preserved according to FAIR principles. SciY combines expertise in data analysis, knowledge extraction, and automation with AI-powered experimentation to streamline traditionally time‑consuming processes. The result is an integrated, governed, and scalable environment to accelerate innovation, harmonize operations, de-risk scale-up and drive products to market faster with consistent quality. For more information, visit www.sciy.com.

Contacts

Media Contact:
Markus Ziegler
Sr. Director and Head of Group Marketing, Bruker BioSpin
T: +49 172 3733531
E: info@sciy.com

Bruker Corporation

NASDAQ:BRKR

Release Versions
$Cashtags
Hashtags

Contacts

Media Contact:
Markus Ziegler
Sr. Director and Head of Group Marketing, Bruker BioSpin
T: +49 172 3733531
E: info@sciy.com

Social Media Profiles
More News From Bruker Corporation

Bruker Showcases Expanding Microbiology & Infection Diagnostics Portfolio at ASM Microbe 2026

WASHINGTON--(BUSINESS WIRE)--At ASM Microbe 2026, Bruker Corporation’s (Nasdaq: BRKR) Microbiology & Infection Diagnostics (BMID) division is demonstrating its expanding portfolio and innovations across microbial identification, sepsis diagnostics, molecular testing, and NGS workflows, advancing clinical research, and faster, actionable infectious disease diagnostics. During the ASM 2026 meeting, Bruker showcases the expanded clinical capabilities of the MALDI Biotyper® CA System enabled by...

Bruker Launches new timsMRMS Mass Spectrometry Platform for Unique Ultra-Complex Mixture Applications in the Energy Industry

SAN DIEGO--(BUSINESS WIRE)--At ASMS, Bruker Corporation (Nasdaq: BRKR) announced the launch of the new timsMRMS system, designed to empower researchers in petroleomics, sustainable fuels and advanced energy storage. The timsMRMS is an innovative platform that combines Trapped Ion Mobility Spectrometry (TIMS) with extreme-resolution Magnetic Resonance Mass Spectrometry (MRMS), to unravel the complex molecular makeup of challenging fossil fuels and green energy materials. It accomplishes this wit...

Bruker Announces Major Strides in 4D Proteomics Performance, Further Advances In Intact and Top-Down Functional Proteoform Analysis, and Innovations in Hybrid Qual/Quant 4D Metabolomics – all to Enable Deeper Insights into Disease Biology

SAN DIEGO--(BUSINESS WIRE)--At ASMS, Bruker Corporation (Nasdaq: BRKR) announced the launch of the unique timsMRMS system, bringing the power of trapped ion mobility separation to ultra-high-resolution magnetic resonance mass spectrometry (MRMS). A translational oncology research initiative by Prof. Stephan Singer at University Hospital Tübingen enables therapy selection, measuring more than 10,000 proteins in FFPE biopsies to reveal actionable tumor biology when precision genomics is inconclus...
Back to Newsroom